LYEL vs. WVE, ORIC, PRAX, TRVI, COLL, RAPP, MAZE, CRON, IMTX, and VALN
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include WAVE Life Sciences (WVE), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Trevi Therapeutics (TRVI), Collegium Pharmaceutical (COLL), Rapport Therapeutics (RAPP), Maze Therapeutics (MAZE), Cronos Group (CRON), Immatics (IMTX), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs. Its Competitors
WAVE Life Sciences (NASDAQ:WVE) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
WAVE Life Sciences has higher revenue and earnings than Lyell Immunopharma. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
WAVE Life Sciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. WAVE Life Sciences' return on equity of -78.45% beat Lyell Immunopharma's return on equity.
In the previous week, Lyell Immunopharma had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.66 beat Lyell Immunopharma's score of 1.15 indicating that WAVE Life Sciences is being referred to more favorably in the media.
89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 24.0% of WAVE Life Sciences shares are held by insiders. Comparatively, 22.3% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
WAVE Life Sciences has a beta of -1.37, meaning that its stock price is 237% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500.
WAVE Life Sciences currently has a consensus target price of $20.33, indicating a potential upside of 181.63%. Lyell Immunopharma has a consensus target price of $15.00, indicating a potential downside of 15.97%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Lyell Immunopharma.
Summary
WAVE Life Sciences beats Lyell Immunopharma on 12 of the 16 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 10/6/2025 by MarketBeat.com Staff
